• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    6/6/24 12:31:11 PM ET
    $AEMD
    $AHG
    $AONC
    $CODX
    Medical/Dental Instruments
    Health Care
    Real Estate
    Real Estate
    Get the next $AEMD alert in real time by email

    Gainers

    • Virax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million.
    • FibroBiologics (NASDAQ:FBLG) shares rose 45.37% to $9.74. The market value of their outstanding shares is at $318.6 million.
    • Aethlon Medical (NASDAQ:AEMD) stock rose 39.58% to $0.61. The company's market cap stands at $3.1 million.
    • American Oncology Network (NASDAQ:AONC) stock rose 32.96% to $3.0. The market value of their outstanding shares is at $30.6 million.
    • Replimune Group (NASDAQ:REPL) shares rose 29.04% to $7.17. The company's market cap stands at $440.6 million.
    • Co-Diagnostics (NASDAQ:CODX) stock rose 27.18% to $1.31. The market value of their outstanding shares is at $40.9 million.

    Losers

    • Ventyx Biosciences (NASDAQ:VTYX) stock fell 37.9% to $3.28 during Thursday's regular session. The market value of their outstanding shares is at $231.2 million.
    • Fresh2 Group (NASDAQ:FRES) stock decreased by 23.15% to $0.47. The company's market cap stands at $11.4 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) stock declined by 19.95% to $0.11. The company's market cap stands at $1.2 million.
    • Kineta (NASDAQ:KA) shares decreased by 19.3% to $0.5. The market value of their outstanding shares is at $6.1 million.
    • 4D Molecular Therapeutics (NASDAQ:FDMT) shares decreased by 17.34% to $22.55. The company's market cap stands at $1.1 billion.
    • Akso Health Group (NASDAQ:AHG) stock declined by 14.42% to $0.89. The company's market cap stands at $130.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $AHG
    $AONC
    $CODX

    CompanyDatePrice TargetRatingAnalyst
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    4D Molecular Therapeutics Inc.
    $FDMT
    11/7/2025Underweight → Equal-Weight
    Morgan Stanley
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Replimune Group Inc.
    $REPL
    11/3/2025$11.00Underperform → Market Perform
    BMO Capital Markets
    Replimune Group Inc.
    $REPL
    10/27/2025$12.00Neutral → Buy
    H.C. Wainwright
    Replimune Group Inc.
    $REPL
    10/20/2025$13.00Neutral → Overweight
    Piper Sandler
    Replimune Group Inc.
    $REPL
    10/20/2025Underweight → Neutral
    Analyst
    Replimune Group Inc.
    $REPL
    10/20/2025$13.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $AEMD
    $AHG
    $AONC
    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

    SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that Jim Frakes, CEO and CFO, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. DATE: Thursday, March 12thTIME: 1:00 – 1:30 pm ET REGISTER HERE Available for 1x1 meetings: March 12th. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportun

    3/6/26 8:35:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

    HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs). The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics' investigational topica

    3/5/26 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

    Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping regenerative medicine[1]. CAR T-cell therapy alone is valued at nearly $7 billion this year, expanding at an 18% compound annual growth rate as off-the-shelf platforms eliminate the logistical barriers that once limited patient access[2]. Among the companies advancing next-generation cell-based treatments are Avaí Bio (OTCQB:AVAI), FibroBiologics (NASDAQ:FBLG), Fate Therapeutics (NASDAQ:FATE), Mesoblast (NASDAQ:MESO), and Longeve

    3/3/26 10:02:00 AM ET
    $FATE
    $FBLG
    $LGVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AEMD
    $AHG
    $AONC
    $CODX
    SEC Filings

    View All

    SEC Form EFFECT filed by Ventyx Biosciences Inc.

    EFFECT - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/9/26 12:15:03 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Ventyx Biosciences Inc.

    EFFECT - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/9/26 12:15:04 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    3/6/26 4:03:48 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AHG
    $AONC
    $CODX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/4/26 5:50:10 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/3/26 8:00:20 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AHG
    $AONC
    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on 4D Molecular Therapeutics with a new price target

    Barclays resumed coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $33.00

    1/28/26 7:14:57 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4D Molecular Therapeutics upgraded by Morgan Stanley

    Morgan Stanley upgraded 4D Molecular Therapeutics from Underweight to Equal-Weight

    11/7/25 8:04:44 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AHG
    $AONC
    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $AHG
    $AONC
    $CODX
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    4DMT Appoints Kristian Humer as Chief Financial Officer

    EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience

    11/17/25 6:00:00 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $AHG
    $AONC
    $CODX
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $AHG
    $AONC
    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/15/24 5:05:27 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/14/24 5:46:12 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care